U.S. patent number 4,727,138 [Application Number 06/774,838] was granted by the patent office on 1988-02-23 for human immune interferon.
This patent grant is currently assigned to Genentech, Inc.. Invention is credited to David V. Goeddel, Patrick Gray.
United States Patent |
4,727,138 |
Goeddel , et al. |
February 23, 1988 |
Human immune interferon
Abstract
Disclosed is a complete description of the preparation of novel,
substantially pure polypeptide via recombinant DNA techniques
utilizing any of an assortment of expression vectors and host
cultures. The polypeptide, human immune (gamma) interferon
(IFN-.gamma.), is isolated and characterized in terms of DNA and
amino acid sequences, physical attributes and biological
activity.
Inventors: |
Goeddel; David V. (Burlingame,
CA), Gray; Patrick (San Francisco, CA) |
Assignee: |
Genentech, Inc. (South San
Francisco, CA)
|
Family
ID: |
23211703 |
Appl.
No.: |
06/774,838 |
Filed: |
September 11, 1985 |
Related U.S. Patent Documents
|
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
Issue Date |
|
|
746813 |
Jun 20, 1985 |
|
|
|
|
312489 |
Oct 19, 1981 |
|
|
|
|
Current U.S.
Class: |
536/23.52;
435/69.51; 435/243; 435/317.1; 435/320.1; 435/811; 530/351;
930/142; 930/300; 435/91.41; 536/25.1 |
Current CPC
Class: |
C12N
15/71 (20130101); C12P 21/02 (20130101); A61P
43/00 (20180101); C07K 14/57 (20130101); C12N
15/81 (20130101); A61P 35/00 (20180101); C12N
15/85 (20130101); A61P 31/12 (20180101); Y10S
930/30 (20130101); Y10S 930/142 (20130101); Y10S
435/811 (20130101); A61K 38/00 (20130101) |
Current International
Class: |
C12N
15/71 (20060101); C12N 15/85 (20060101); C12N
15/81 (20060101); C07K 14/435 (20060101); C07K
14/57 (20060101); C12P 21/02 (20060101); A61K
38/00 (20060101); C07H 021/02 (); C12P 021/00 ();
C12P 021/02 (); C12P 021/04 (); C12P 019/34 (); C12N
001/20 (); C12N 015/00 (); C12N 005/00 (); C12N
001/00 (); C07K 013/00 () |
Field of
Search: |
;435/68,70,172.3,91,317,253,255,256,243,240,235,241,811,172.1,317.1,240.2
;935/11,27,28,29,68-75,60 ;536/27 ;530/320,351 |
References Cited
[Referenced By]
U.S. Patent Documents
Foreign Patent Documents
|
|
|
|
|
|
|
0028033 |
|
May 1981 |
|
EP |
|
0063482 |
|
Oct 1982 |
|
EP |
|
WO81/3498 |
|
Dec 1981 |
|
WO |
|
2040292 |
|
Aug 1980 |
|
GB |
|
2063882 |
|
Jun 1981 |
|
GB |
|
2068970 |
|
Aug 1981 |
|
GB |
|
2071108 |
|
Sep 1981 |
|
GB |
|
2091268 |
|
Jul 1982 |
|
GB |
|
Other References
Gene Expression, vol. 2, Eucaryotic Chromosomes, Lewin, 1974, John
Wiley & Sons, New York, pp. 148-156. .
de Ley, M. et al., Eur. J. Immunol., 10: 877 (1980). .
Yip, Y. K. et al.; Proc. Nat. Acad. Sci. (U.S.A.) 78: 1601 (1981).
.
Berger, S. L. et al., J. Biol. Chem., 225: 2955 (1980). .
Botstein et al.; Recomb. DNA Tech. Bull. 2, 49 (1979). .
Dianzani et al.; Nature 283, 400 (1980). .
Wallace et al.; Fed.Proc. 40, 1574 (1981). .
Wallace et al.; Biochem. Biophys. Res. Commun. 100, 865 (1981).
.
Taniguchi et al.; Proc. Natl. Acad. Sci. U.S.A. 78, 3469 (1981).
.
Epstein, L. B., Fed. Proc., 40, 56 (1981). .
Vilcek, J. et al.; Microbiol., 204-207 (1980). .
Novokhatskii et al.; Chem. Abstr. 96, 120770e (1982) first pub. in
Dokl. Akad. Nauk SSSR, 261 997 (1981). .
Goeddel et al.; Nature 287, 411 (1980). .
Hamer et al.; Nature 281, 35 (1979). .
Weissman, in Interferon 1981, vol. 3, Gresser (ed.), Academic
Press, 1981, pp. 101-134. .
Vilcek, in Interferon 1982, vol. 4, Academic Press, 1982, pp.
129-154. .
Murray, Annals of Internal Medicine, 98, 1016 (1983). .
Life, May 1980, pp. 50-54. .
Time, Mar. 31, 1980, pp. 60-66. .
Devos et al. Nucl. Acids Res. 10, 2487 (1982). .
Epstein, Nature 295, 453 (1982). .
Epstein, in Interferon 1981, Vo. 3, Gresser (ed.), Academic Press,
1981, pp. 13-44. .
Nathan et al., Nature 292, 842-844 (1981). .
Yip et al., Science 215, 411 (1982). .
Genetic Engineering Letter, vol. 2, No. 17, "Artificial Gene for
Gamma Interferon Reported by Japanese Scientist" (1982). .
Newmark, Nature 294, 7 (1981)..
|
Primary Examiner: Martinell; James
Parent Case Text
This is a division of application Ser. No. 746,813, filed June 20,
1985, pending, which is a continuation of application Ser. No.
312,489, filed Oct. 19, 1981, now abandoned.
Claims
What is claimed is:
1. A DNA molecule comprising a recombinant DNA molecule or a cDNA
molecule encoding a polypeptide comprising the amino acid sequence:
##STR3##
2. A DNA molecule comprising a recombinant DNA molecule or a cDNA
molecule encoding a polypeptide comprising the amino acid sequence:
##STR4##
3. A DNA molecule according to claim 1 or claim 2 operably linked
with a DNA sequence capable of effecting expression of the DNA
encoding said polypeptide.
4. A molecule consisting essentially of a DNA molecule encoding the
amino acid sequence of recombinant human immune interferon.
5. A molecule consisting essentially of a DNA molecule encoding the
amino acid sequence of des-CYS-TYR-CYS recombinant human immune
interferon.
Description
FIELD OF THE INVENTION
The present invention relates to the field of recombinant DNA
technology, to means and methods utilizing such technology in the
discovery of the DNA sequence and deduced amino acid sequence for
human immune interferon and to its production and to the various
products of such production and their uses.
More particularly, the present invention relates to the isolation
and identification of DNA sequences encoding human immune
interferon and to the construction of recombinant DNA expression
vehicles containing such DNA sequences operably linked to
expression-effecting promoter sequences and to the expression
vehicles so constructed. In another aspect, the present invention
relates to host culture systems, such as various microorganism and
vertebrate cell cultures transformed with such expression vehicles
and thus directed in the expression of the DNA sequences referred
to above. In yet other aspects, this invention relates to the means
and methods of converting the end products of such expression to
novel entities, such as pharmaceutical compositions, useful for the
prophylactic or therapeutic treatment of humans. In preferred
embodiments, this invention provides particular expression vehicles
that are sequenced properly such that human immune interferon is
produced and secreted from the host cell in mature form. In
addition, this invention relates to various processes useful for
producing said DNA sequences, expression vehicles, host culture
systems and end products and entities thereof and to specific and
associated embodiments thereof.
The present invention arises in part from the discovery of the DNA
sequence and deduced amino acid sequence encoding human immune
interferon. In addition, the present invention provides sequence
information on the 3'- and 5'-flanking sequences of the human
immune interferon gene, facilitating the in vitro linkage thereof
into expression vehicles. In particular, there is provided the
5'-DNA segment encoding the putative endogenous signal polypeptide
which immediately precedes the amino acid sequence of the putative
mature human immune interferon. These discoveries, in turn, have
enabled the development of the means and methods for producing, via
recombinant DNA technology, sufficient amounts of human immune
interferon, so as to enable, in turn, the determination of its
biochemical properties and bioactivity. The publications and other
materials hereof used to illuminate the background of the
invention, and in particular cases, to provide additional details
respecting its practice are incorporated herein by reference, and
for convenience, are numerically referenced by the following text
and respectively grouped in the appended bibliography.
BACKGROUND OF THE INVENTION
A. Human Immune Interferon
Human interferons can be classified in three groups on the basis of
different antigenicity and biological and biochemical
properties.
The first group comprises a family of leukocyte interferons
(.alpha.-interferon, LeIF or IFN-.alpha.), which are normally
produced mainly by constituent cells of human blood upon viral
induction. These have been microbially produced and found to be
biologically active (1, 2, 3). Their biological properties have
prompted their use in the clinic as therapeutic agents for the
treatment of viral infections and malignant conditions (4).
In the second group is human fibroblast interferon
(.beta.-interferon, FIF or IFN-.beta.), normally produced by
fibroblasts upon viral induction, which has likewise been
microbially produced and found to exhibit a wide range of
biological activities (5). Clinical trials also indicate its
potential therapeutic value. The leukocyte and fibroblast
interferons exhibit very clear similarities in their biological
properties despite the fact that the degree of homology at the
amino acid level is relatively low. In addition, both groups of
interferons contain from 165 to 166 amino acids and are acid stable
proteins.
The human immune interferon (.gamma.-interferon, IIF or
IFN-.gamma.), to which this invention is directed, is, in contrast
to the .alpha.- and .beta.-interferons, pH 2 labile, is produced
mainly upon mitogenic induction of lymphocytes and is also clearly
antigenically distinct. Until recently human immune interferon
could only be detected in very minor levels, which evidently
hampered its characterization. Recently, a rather extensive but
still partial purification of human immune interferon has been
reported (6). The compound was said to be produced from lymphocyte
cultures stimulated with a combination of phytohaemagglutin and a
phorbol ester and purified by sequential chromatographic
separations. This procedure resulted in a product having a
molecular weight of 58,000.
Human immune interferon has been produced in very low amounts by
translating mRNA in oocytes, showing interferon activity
characteristic of human immune interferon and expressing the hope
that immune interferon cDNA could be synthesized and cloned
(7).
The amount of immune interferon obtained until now is certainly
insufficient to carry out unambiguous experiments on the
characterization and biological properties of the purified
component. However, in vitro studies performed with crude
preparations, as well as in vivo experiments with murine
.gamma.-interferon preparations, suggest that the primary function
of immune interferon may be as an immunoregulatory agent (8, 9).
Immune interferon has not only an antiviral and anticellular
activity in common to all human interferons, but shows a
potentiating effect on these activities with .alpha.- and
.beta.-interferon (10). Also, the in vitro antiproliferative effect
of .gamma.-interferon on tumor cells is reported to be
approximately 10- to 100-fold that of the other interferon classes
(8, 11, 12). This result, together with its pronounced
immunoregulatory role (8, 9), suggests a much more pronounced
antitumoral potency for IFN-.gamma. than for IFN-.alpha. and
IFN-.beta.. Indeed, in vivo experiments with mice and murine
IFN-.gamma. preparations show a clear superiority over antivirally
induced interferons in its antitumoral effect against osteogenic
sarcoma (13).
All of these studies, until the present invention, had to be
performed with rather crude preparations, due to the very low
availability. However, they certainly suggest very important
biological functions for immune interferon. Not only has immune
interferon a potent associated antiviral activity, but probably
also a strong immunoregulatory and antitumoral activity, clearly
pointing to a potentially very promising clinical candidate.
It was perceived that the application of recombinant DNA technology
would be a most effective way of providing the requisite larger
quantities of human immune interferon. Whether or not the materials
so produced would include glycosylation which is considered
characteristic of native, human derived material, they would
probably exhibit bioactivity admitting of their use clinically in
the treatment of a wide range of viral, neoplastic, and
immunosuppressed conditions or diseases.
B. Recombinant DNA Technology
Recombinant DNA technology has reached the age of some
sophistication. Molecular biologists are able to recombine various
DNA sequences with some facility, creating new DNA entities capable
of producing copious amounts of exogenous protein product in
transformed microbes. The general means and methods are in hand for
the in vitro ligation of various blunt ended or "sticky" ended
fragments of DNA, producing potent expression vehicles useful in
transforming particular organisms, thus directing their efficient
synthesis of desired exogenous product. However, on an individual
product basis, the pathway remains somewhat tortuous and the
science has not advanced to a stage where regular predictions of
success can be made. Indeed, those who portend successful results
without the underlying experimental basis, do so with considerable
risk of inoperability.
The plasmid, a nonchromosomal loop of double-stranded DNA found in
bacteria and other microbes, oftentimes in multiple copies per
cell, remains a basic element of recombinant DNA technology.
Included in the information encoded in the plasmid DNA is that
required to reproduce the plasmid in daughter cells (i.e., an
origin of replication) and ordinarily, one or more phenotypic
selection characteristics such as, in the case of bacteria,
resistance to antibiotics, which permit clones of the host cell
containing the plasmid of interest to be recognized and
preferentially grown in selective media. The utility of plasmids
lies in the fact that they can be specifically cleaved by one or
another restriction endonuclease or "restriction enzyme", each of
which recognizes a different site on the plasmid DNA. Thereafter
heterologous genes or gene fragments may be inserted into the
plasmid by endwise joining at the cleavage site or at reconstructed
ends adjacent to the cleavage site. Thus formed are so-called
replicable expression vehicles. DNA recombination is performed
outside the cell, but the resulting "recombinant" replicable
expression vehicle, or plasmid, can be introduced into cells by a
process known as transformation and large quantities of the
recombinant vehicle obtained by growing the transformant. Moreover,
where the gene is properly inserted with reference to portions of
the plasmid which govern the transcription and translation of the
encoded DNA message, the resulting expression vehicle can be used
to actually produce the polypeptide sequence for which the inserted
gene codes, a process referred to as expression.
Expression is initiated in a region known as the promoter which is
recognized by and bound by RNA polymerase. In the transcription
phase of expression, the DNA unwinds, exposing it as a template for
initiated synthesis of messenger RNA from the DNA sequence. The
messenger RNA is, in turn, translated into a polypeptide having the
amino acid sequence encoded by the mRNA. Each amino acid is encoded
by a nucleotide triplet or "codon" which collectively make up the
"structural gene", i.e. that part which encodes the amino acid
sequence of the expressed polypeptide product. Translation is
initiated at a "start" signal (ordinarily ATG, which in the
resulting messenger RNA becomes AUG). So-called stop codons define
the end of translation and, hence, of production of further amino
acid units. The resulting product may be obtained by lysing, if
necessary, the host cell, in microbial systems, and recovering the
product by appropriate purification from other proteins.
In practice, the use of recombinant DNA technology can express
entirely heterologous polypeptides--so-called direct expression--or
alternatively may express a heterologous polypeptide fused to a
portion of the amino acid sequence of a homologous polypeptide. In
the latter cases, the intended bioactive product is sometimes
rendered bioinactive within the fused, homologous/heterologous
polypeptide until it is cleaved in an extracellular environment.
See British Pat. Publ. No. 2007676A and Wetzel, American Scientist
68, 664 (1980).
C. Cell Culture Technology
The art of cell or tissue cultures for studying genetics and cell
physiology is well established. Means and methods are in hand for
maintaining permanent cell lines, prepared by successive serial
transfers from isolate normal cells. For use in research, such cell
lines are maintained on a solid support in liquid medium, or by
growth in suspension containing support nutriments. Scale-up for
large preparations seems to pose only mechanical problems. For
further background, attention is directed to Microbiology, 2nd
Edition, Harper and Row, Publishers, Inc, Hagerstown, Md. (1973)
especially pp. 1122 et seq. and Scientific American 245, 66 et seq.
(1981), each of which is incorporated herein by this reference.
SUMMARY OF THE INVENTION
The present invention is based upon the discovery that recombinant
DNA technology can be used to successfully produce human immune
interferon, preferably in direct form, and in amounts sufficient to
initiate and conduct animal and clinical testing as prerequisites
to market approval. The product is suitable for use, in all of its
forms, in the prophylactic or therapeutic treatment of human beings
for viral infections and malignant and immunosuppressed or
immunodeficient conditions. Its forms include various possible
oligomeric forms which may include associated glycosylation. The
product is produced by genetically engineered transformant
microorganisms or transformant cell culture systems. As used
herein, the term "transformant cell" refers to a cell into which
has been introduced DNA, said DNA arising from exogenous DNA
recombination, and to the progeny of any such cell which retains
the DNA so introduced. Thus, the potential now exists to prepare
and isolate human immune interferon in a more efficient manner than
has been possible. One significant factor of the present invention,
in its most preferred embodiments, is the accomplishment of
genetically directing a microorganism or cell culture to produce
human immune interferon in isolatable amounts, secreted from the
host cell in mature form.
The present invention comprises the human immune interferon thus
produced and the means and methods of its production. The present
invention is further directed to replicable DNA expression vehicles
harboring gene sequences encoding human immune interferon in
expressible form. Further, the present invention is directed to
microorganism strains or cell cultures transformed with the
expression vehicles described above and to microbial or cell
cultures of such transformed strains or cultures, capable of
producing human immune interferon. In still further aspects, the
present invention is directed to various processes useful for
preparing said immune interferon gene sequences, DNA expression
vehicles, microorganism strains and cell cultures and to specific
embodiments thereof. Still further, this invention is directed to
the preparation of fermentation cultures of said microorganisms and
cell cultures. In addition, this invention is directed to the
preparation of human immune interferon, as a direct expression
product, secreted from the host cell in mature form. This approach
may utilize the gene encoding the sequence of the mature human
immune interferon plus the 5' flanking DNA encoding the signal
polypeptide. The signal polypeptide is believed to aid in the
transport of the molecule to the cellular wall of the host
organisms where it is cleaved during the secretion process of the
mature human interferon product. This embodiment enables the
isolation and purification of the intended mature immune interferon
without resort to involved procedures designed to eliminate
contaminants of intracellular host protein or cellular debris.
Reference herein to the expression "mature human immune interferon"
connotes the microbial or cell culture production of human immune
interferon unaccompanied by the signal peptide or presequence
peptide that immediately attends translation of the human immune
interferon mRNA. A first recombinant human immune interferon,
according to the present invention, is thus provided, having
methionine as its first amino acid (present by virtue of the ATG
start signal codon insertion in front of the structural gene) or,
where the methionine is intra- or extracellularly cleaved, having
its normally first amino acid cysteine. Mature human immune
interferon can also be produced, in accordance herewith, together
with a conjugated protein other than the conventional signal
polypeptide, the conjugate being specifically cleavable in an
intra- or extracellular environment. See British Pat. publication
No. 2007676A. Finally, the mature human immune interferon can be
produced by direct expression without the necessity of cleaving
away any extraneous, superfluous polypeptide. This is particularly
important where a given host may not, or not efficiently, remove a
signal peptide where the expression vehicle is designed to express
the mature human interferon together with its signal peptide. The
thus produced mature human immune interferon is recovered and
purified to a level fitting it for use in the treatment of viral,
malignant, and immunosuppressed or immunodeficient conditions.
Human immune interferon was obtained according to the
following:
1. Human tissues, for example human spleen tissue or peripheral
blood lymphocytes, were cultured with mitogens to stimulate the
production of immune interferon.
2. Cell pellets from such cell cultures were extracted in the
presence of ribonuclease inhibitor to isolate all cytoplasmic
RNA.
3. An oligo-dT column isolated the total messenger RNA (mRNA) in
polyadenylated form. This mRNA was size-fractionated using sucrose
density gradient and acid-urea gel electrophoresis.
4. The appropriate mRNA (12 to 18 S) was converted to corresponding
single stranded complementary DNA (cDNA) from which was produced
double stranded cDNA. After poly-dC tailing, it was inserted into a
vector, such as a plasmid bearing one or more phenotypic
markers.
5. The thus prepared vectors were used to transform bacterial cells
providing a colony library. Radiolabeled cDNA prepared from both
induced and uninduced mRNA, derived as described above, was used to
separately probe duplicate colony libraries. The excess cDNA was
then removed and the colonies exposed to X-ray film so as to
identify the induced cDNA clones.
6. From the induced cDNA clones the corresponding plasmid DNA was
isolated and sequenced.
7. In a first embodiment sequenced DNA was then tailored in vitro
for insertion into an appropriate expression vehicle which was used
to transform an E. coli host cell which was, in turn, permitted to
grow in a culture and to express the desired human immune
interferon product.
8. Human immune interferon thus expressed doubtless has 146 amino
acids in its mature form, beginning with cysteine, and is very
basic in character. Its monomeric molecular weight has been
calculated at 17,140. Perhaps because of the presence of numerous
basic residues, hydrophobicity, salt bridge formation and so forth,
the molecule may associate itself in oligomeric forms, e.g., in
dimer, trimer or tetramer form. The high molecular weights
previously observed with natural material (6) which can not be
accounted for on the basis of the amino acid sequence alone may be
due to such oligomeric forms as well as to the contribution of
carbohydrate from post-translational glycosylation.
9. In certain host cell systems, particularly when ligated into an
expression vehicle so as to be expressed together with its signal
peptide, the mature form of human immune interferon is exported
into the cell culture medium, immeasurably aiding in recovery and
purification methods.
DESCRIPTION OF PREFERRED EMBODIMENTS
A. Microorganisms/Cell Cultures
1. Bacterials Strains/Promoters
The work described herein was performed employing, inter alia, the
microorganism E. coli K-12 strain 294 (end A, thi.sup.-, hsr.sup.-,
.sub.k hsm.sup.+), as described in British Pat. Publication No.
2055382 A. This strain has been deposited with the American Type
Culture Collection, ATCC Accession No. 31446. However, various
other microbial strains are useful, including known E. coli strains
such as E. coli B, E. coli X 1776 (ATCC No. 31537) and E. coli W
3110 (F.sup.-, .lambda..sup.-, protrophic) (ATCC No. 27325), or
other microbial strains many of which are deposited and
(potentially) available from recognized microorganism depository
institutions, such as the American Type Culture Collection
(ATCC)--cf. the ATCC catalogue listing. See also German
Offenlegungsschrift No. 2644432. These other microorganisms
include, for example, Bacilli such as Bacillus subtilis and other
enterobacteriaceae among which can be mentioned as examples
Salmonella typhimurium and Serratia marcesans, utilizing plasmids
that can replicate and express heterologous gene sequences
therein.
As examples, the beta lactamase and lactose promoter systems have
been advantageously used to initiate and sustain microbial
production of heterologous polypeptides. Details relating to the
make-up and construction of these promoter systems have been
published by Chang et al., Nature 275, 617 (1978) and Itakura et
al., Science 198, 1056 (1977), which are hereby incorporated by
reference. More recently, a system based upon tryptophan, the
so-called trp promoter system, has been developed. Details relating
to the make-up and construction of this system have been published
by Goeddel et al., Nucleic Acids Research 8, 4057 (1980) and Kleid
et al., U.S. Ser. No. 133, 296, filed Mar. 24, 1980, which are
hereby incorporated by reference. Numerous other microbial
promoters have been discovered and utilized and details concerning
their nucleotide sequences, enabling a skilled worker to ligate
them functionally within plasmid vectors, have been published--see,
e.g., Siebenlist et al., Cell 20, 269 (1980), which is incorporated
herein by this reference.
2. Yeast Strains/Yeast Promoters
The expression system hereof may also employ the plasmid YRp7 (14,
15, 16), which is capable of selection and replication in both E.
coli and the yeast, Saccharomyces cerevisiae. For selection in
yeast the plasmid contains the TRP1 gene (14, 15, 16) which
complements (allows for growth in the absence of tryptophan) yeast
containing mutations in this gene found on chromosome IV of yeast
(17). The strain used here was the strain RH218 (18) deposited at
the American Type Culture Collection without restriction (ATCC No.
44076). However, it will be understood that any Saccharomyces
cerevisiae strain containing a mutation which makes the cell trp1
should be an effective environment for expression of the plasmid
containing the expression system. An example of another strain
which could be used is pep4-1 (19). This tryptophan auxotroph
strain also has a point mutation in TRP1 gene.
When placed on the 5' side of a non-yeast gene the 5'-flanking DNA
sequence (promoter) from a yeast gene (for alcohol dehydrogenase 1)
can promote the expression of a foreign gene in yeast when placed
in a plasmid used to transform yeast. Besides a promoter, proper
expression of a non-yeast gene in yeast requires a second yeast
sequence placed at the 3'-end of the non-yeast gene on the plasmid
so as to allow for proper transcription termination and
polyadenylation in yeast. This promoter can be suitably employed in
the present invention as well as others--see infra. In the
preferred embodiments, the 5'-flanking sequence of the yeast
3-phosphoglycerate kinase gene (20) is placed upstream from the
structural gene followed again by DNA containing
termination--polyadenylation signals, for example, the TRP1 (14,
15, 16) gene or the PGK (20) gene.
Because yeast 5'-flanking sequence (in conjunction with 3' yeast
termination DNA) (infra) can function to promote expression of
foreign genes in yeast, it seems likely that the 5'-flanking
sequence of any highly-expressed yeast gene could be used for the
expression of important gene products. Since under some
circumstances yeast expressed up to 65 percent of its soluble
protein as glycolytic enzymes (21) and since this high level
appears to result from the production of high levels of the
individual mRNAs (22), it should be possible to use the 5'-flanking
sequences of any other glycolytic genes for such expression
purposes--e.g., enolase, glyceraldehyde--3-phosphate dehydrogenase,
hexokinase, pyruvate decarboxylase, phosphofructokinase,
glucose--6-phosphate isomerase, 3-phosphoglycerate mutase, pyruvate
kinase, triosephosphate isomerase, phosphoglucose isomerase, and
glucokinase. Any of the 3'-flanking sequences of these genes could
also be used for proper termination and mRNA polyadenylation in
such an expression system--cf. Supra. Some other highly expressed
genes are those for the acid phosphatases (23) and those that
express high levels of production due to mutations in the
5'-flanking regions (mutants that increase expression)--usually due
to the presence of a TYl transposable element (24).
All of the genes mentioned above are thought to be transcribed by
yeast RNA polymerase II (24). It is possible that the promoters for
RNA polymerase I and III which transcribe genes for ribosomal RNA,
5S RNA, and tRNAs (24, 25), may also be useful in such expression
constructions.
Finally, many yeast promoters also contain transcriptional control
so they may be turned off or on by variation in growth conditions.
Some examples of such yeast promoters are the genes that produce
the following proteins: Alcohol dehydrogenase II, isocytochrome-c,
acid phosphatase, degradative enzymes associated with nitrogen
metabolism, glyceraldehyde-3-phosphate dehydrogenase, and enzymes
responsible for maltose and galactose utilization (22). Such a
control region would be very useful in controlling expression of
protein product--especially when their production is toxic to
yeast. It should also be possible to put the control region of one
5'-flanking sequence with a 5'-flanking sequence containing a
promoter from a highly expressed gene. This would result in a
hybrid promoter and should be possible since the control region and
the promoter appear to be physically distinct DNA sequences.
3. Cell Culture Systems/Cell Culture Vectors
Propogation of vertebrate cells in culture (tissue culture) has
become a routine procedure in recent years (see Tissue Culture,
Academic Press, Kruse and Patterson eds, 1973). Employed herein was
the COS-7 line of monkey kidney fibroblasts as the host for the
production of immune interferon (25a). However, the experiments
detailed here could be performed in any cell line which is capable
of the replication and expression of a compatible vector, e.g.,
WI38, BHK, 3T3, CHO, VERO, and HeLa cell lines. Additionally, what
is required of the expression vector is an origin of replication
and a promoter located in front of the gene to be expressed, along
with any necessary ribosome binding sites, RNA splice sites,
polyadenylation site, and transcriptional terminator sequences.
While these essential elements of SV40 have been exploited herein,
it will be understood that the invention, although described herein
in terms of a preferred embodiment, should not be construed as
limited to these sequences. For example, the origin of replication
of other viral (e.g., Polyoma, Adeno, VSV, BPV, and so forth)
vectors could be used, as well as cellular origins of DNA
replication which could function in a nonintegrated state.
B. Vector Systems
1. Direct Expression of Mature Immune Interferon in E. coli
The procedure used to obtain direct expression of IFN-.gamma. in E.
coli as a mature interferon polypeptide (minus signal sequence) was
a variant of that employed earlier for human growth hormone (26)
and human leukocyte interferon (1), insofar as it involved the
combination of synthetic (N-terminal) and cDNAs.
As deduced from the nucleotide sequence of p69, described infra,
and by comparison with the known cleavage site between signal
peptide and mature polypeptide for several IFN-.alpha.s (2),
IFN-.gamma. has a hydrophobic signal peptide of 20 amino acids
followed by 146 amino acids of mature IFN-.gamma. (FIG. 5). As
shown in FIG. 7, a BstNI restriction endonuclease site is
conveniently located at amino acid 4 of mature IFN-.gamma.. Two
synthetic oligodeoxynucleotides were designed which incorporate an
ATG translational initiation codon, codons for amino acids 1, 2 and
3 (cysteine-tyrosine-cysteine) and create an EcoRI cohesive end.
These deoxyoligonucleotides were ligated to a 100 base pair
BstNI-PstI fragment of p69 to construct a 1115 base pair
synthetic-natural hybrid gene which codes for IFN-.gamma. and which
is bounded by EcoRI and PstI restriction sites. This gene was
inserted into the plasmid pLeIF A trp 103 between the EcoRI and
PstI sites to give the expression plasmid pIFN-.gamma. trp 48. In
this plasmid the IFN-.gamma. gene is expressed under the control of
the E. coli trp promoter. (pLeIF A trp 103 is a derivative of pLeIF
A 25 in which the EcoRI site distal to the LeIF A gene was removed.
The procedure used to remove this EcoRI site has been described
previously (27)).
2. Expression in Yeast
To express a heterologous gene such as the cDNA for immune
interferon in yeast, it was necessary to construct a plasmid vector
containing four components. The first component is the part which
allows for transformation of both E. coli and yeast and thus must
contain a selectable gene from each organism. (In this case, this
is the gene for ampicillin resistance from E. coli and the gene
TRP1 from yeast.) This component also requires an origin of
replication from both organisms to be maintained as a plasmid DNA
in both organisms. (In this case, this is the E. coli origin from
pBR322 and the ars1 origin from chromosome III of yeast.)
The second component of the plasmid is a 5'-flanking sequence from
a highly expressed yeast gene to promote transcription of a
downstream-placed structural gene. In this case, the 5'-flanking
sequence used is that from the yeast 3-phosphoglycerate kinase
(PGK) gene. The fragment was constructed in such a way so as to
remove the ATG of the PGK structural sequence as well as 8 bp
upstream from this ATG. This sequence was replaced with a sequence
containing both an XbaI and EcoRI restriction site for convenient
attachment of this 5'-flanking sequence to the structural gene.
The third component of the system is a structural gene constructed
in such a manner that it contains both an ATG translational start
and translational stop signals. The isolation and construction of
such a gene is described infra.
The fourth component is a yeast DNA sequence containing the
3'-flanking sequence of a yeast gene, which contains the proper
signals for transcription termination and polyadenylation.
With all these components present, immune interferon has been
produced in yeast.
3. Expression in Mammalian Cell Culture
The strategy for the synthesis of immune interferon in mammalian
cell culture relied on the development of a vector capable of both
autonomous replication and expression of a foreign gene under the
control of a heterologous transcriptional unit. The replication of
this vector in tissue culture was accomplished by providing a DNA
replication origin (derived from SV40 virus), and providing helper
function (T antigen) by the introduction of the vector into a cell
line endogenously expressing this antigen (28, 29). The late
promoter of SV40 virus preceded the structural gene of interferon
and ensured the transcription of the gene.
The vector used to obtain expression of IFN-.gamma. consisted of
pBR322 sequences which provided a selectable marker for selection
in E. coli (ampicillin resistance) as well as an E. coli origin of
DNA replication. These sequences were derived from the plasmid
pML-1 (28) and encompassed the region spanning the EcoRI and BamHI
restriction sites. The SV40 origin is derived from a 342 base pair
PvuII-HindIII fragment encompassing this region (30, 31) (both ends
being converted to EcoRI ends). These sequences, in addition to
comprising the viral origin of DNA replication, encode the promoter
for both the early and last transcriptional unit. The orientation
of the SV40 origin region was such that the promoter for the late
transcriptional unit was positioned proximal to the gene encoding
interferon.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 depicts a sucrose gradient centrifugation of induced
Peripheral Blood Lymphocyte (PBL) Poly(A)+ RNA. Two peaks of
interferon activity were observed (as shown by the hatched boxes)
with sizes of 12S and 16S. The positions of ribosomal RNA markers
(centrifuged independently) are labeled above the absorbance
profile.
FIG. 2 depicts an electrophoresis of induced PBL Poly(A)+ RNA
through an acid-urea-agarose. Only one peak of activity was
observed, which comigrated with 18S RNA. The positions of ribosomal
RNA markers which were electrophoresed in an adjacent lane and
visualized by ethidium bromide staining are labeled above the
activity profile.
FIG. 3 shows hybridization patterns of 96 colonies with induced and
uninduced .sup.32 P-labelled cDNA probes. 96 individual
transformants were grown in a microtiter plate, replica plated on
two nitrocellulose membranes, and then the filters were hybridized
with .sup.32 P-cDNA probes prepared from either induced mRNA
(above) or mRNA isolated from uninduced PBL cultures (uninduced,
below). The filters were washed to remove non-hybridized RNA and
then exposed to X-ray film. This set of filters is representative
of 86 such sets (8300 independent colonies). An example of an
"induced" clone is labelled as H12.
FIG. 4 is a restriction endonuclease map of the clone 69 cDNA
insert. The cDNA insert is bounded by PstI sites (dots at both
ends) and oligo dC-dG tails (single lines). The number and size of
fragments produced by restriction nuclease cleavage was estimated
by electrophoresis through 6 percent acrylamide gels. Positions of
sites was confirmed by nucleic acid sequencing (presented in FIG.
5). The coding region of the largest open reading frame is boxed
and the hatched region represents the putative 20 residue signal
peptide sequence, while the stipled region represents the mature
IIF sequence (146 amino acids). The 5' end of the mRNA is to the
left while the 3' end is to the right.
FIG. 5 illustrates the nucleotide sequence of the plasmid p69 cDNA
insert. The deduced amino acid sequence of the longest open reading
frame is also presented. The putative signal sequence is
represented by the residue labelled S1 to S20.
FIG. 6 is a comparison of IFN-.gamma. mRNA structure with that of
leukocyte (IFN-.alpha.) and fibroblast (IFN-.beta.) interferons.
The clone 69 mRNA (labelled immune) contains significantly greater
amounts of untranslated sequences.
FIG. 7 is a schematic diagram of the construction of the
IFN-.gamma. expression plasmid pIFN-.gamma. trp 48. The starting
material is the 1250 base pair PstI cDNA insert from plasmid
p69.
FIG. 8 shows a diagram of plasmid used for expression of
IFN-.gamma. in monkey cells.
FIG. 9 depicts a Southern hybridization of eight different EcoRI
digested human genomic DNAs hybridized with a .sup.32 P-labelled
600 base pair DdeI fragment from the cDNA insert of p69. Two EcoRI
fragments clearly hybridize with the probe in each DNA sample.
FIG. 10 depicts a Southern hybridization of human genomic DNA
digested with six different restriction endonucleases hybridized
with the .sup.32 P-labelled probe from p69.
FIG. 11 schematically illustrates the restriction map of the 3.1
kbp HindIII insert of vector pB1 from which the PGK promoter was
isolated. Indicated is the insertion of an EcoRI site and an XbaI
site in the 5'-flanking DNA of the PGK gene.
FIG. 12 illustrates the 5'-flanking sequence plus the initial
coding sequence for the PGK gene before insertion of an XbaI and
EcoRI sites.
FIG. 13 schematically illustrates techniques used to insert an XbaI
site at position--8 in the PGK promoter and to isolate a 39 bp
fragment of the 5'-flanking sequence of PGK containing this XbaI
end and a Sau3A end.
FIG. 14 schematically illustrates the construction of a 300 bp
fragment containing the above 39 bp fragment, additional PGK
5'-flanking sequence (265 bp) from PvuI to Sau3A (see FIG. 11), and
a EcoRI site adjacent to XbaI.
FIG. 15 schematically illustrates the construction of the 1500 bp
PGK promoter fragment (HindIII/EcoRI) which contains, in addition
to the fragment constructed in FIG. 14, a 1300 bp HindIII to PvuI
fragment from PGK 5'-flanking sequence (see FIG. 11).
FIG. 16 illustrates the composition of an expression vector for
human immune interferon in yeast, containing the modified PGK
promoter, the IFN-.gamma. cDNA and the terminator region of the
yeast PGK gene as described in more detail herein.
DETAILED DESCRIPTION
A. Source of IFN-.gamma. mRNA
Peripheral Blood Lymphocytes (PBLs) were derived from human donors
by leukophoresis. PBLs were further purified by Ficoll-Hypaque
gradient centrifugation and then cultured at a concentration of
5.times.10.sup.6 cells/ml in RPMI 1640, 1 percent L-glutamine, 25
mM HEPES, and 1 percent penicillin-streptomycin solution (Gibco,
Grand Island, NY). These cells were induced to produce IFN-.gamma.
by the mitogen staphlococcal enterotoxin B (1 .mu.g/ml) and
cultured for 24 to 48 hours at 37.degree. C. in 5 percent CO.sub.2.
Desacetylthymosin-.alpha.-1 (0.1 .mu.g/ml) was added to PBL
cultures to increase the relative yield of IFN-.gamma.
activity.
B. Messenger RNA Isolation
Total RNA from PBL cultures was extracted essentially as reported
by Berger, S. L. et al. (33). Cells were pelleted by centrifugation
and then resuspended in 10 mM NaCl, 10 mM Tris-HCl (pH 7.5), 1.5 mM
MgCl.sub.2 and 10 mM ribonucleoside vanadyl complex. Cells were
lysed by the addition of NP-40 (1 percent final concentration), and
nuclei were pelleted by centrifugation. The supernatant contained
the total RNA which was further purified by multiple phenol and
chloroform extractions. The aqueous phase was made 0.2M in NaCl and
then total RNA was precipitated by the addition of two volumes of
ethanol. RNA from uninduced (nonstimulated) cultures was isolated
by the same methods. Oligo-dT cellulose chromatography was utilized
to purify mRNA from the total RNA preparations (34). Typical yields
from 1-2 liters of cultured PBLs were 5-10 milligrams of total RNA
and 50-200 micrograms of Poly(A)+ RNA.
C. Size Fractionation of mRNA
Two methods were used to fractionate mRNA preparations. These
methods were used independently (rather than in unison) and each
resulted in a significant enrichment of IFN-.gamma. mRNA.
Sucrose gradient centrifugation in the presence of the denaturant
formamide was used to fractionate mRNA. Gradients of 5 percent to
25 percent sucrose in 70 percent formamide (32) were centrifuged at
154,000.times.g for 19 hours at 20.degree. C. Successive fractions
(0.5 ml) were then removed from the top of the gradient, ethanol
precipitated, and an aliquot was injected into Xenopus laevis
oocytes for translation of the mRNA (35). After 24 hrs. at room
temperature, the incubation medium was then assayed for antiviral
activity in a standard cytopathic effect inhibition assay employing
Vesicular Stomatitis Virus (Indiana strain) or Encephalomyocarditis
Virus on WISH (human amnion) cells as described by Stewart (36),
except that the samples were incubated with the cells for 24 hours
(instead of 4) prior to challenge with the virus. Two activity
peaks were consistently observed in sucrose gradient fractionated
RNA (FIG. 1). One peak sedimented with a calculated size of 12S and
contained 100-400 units/ml of antiviral activity (compared with a
IFN-.alpha. standard) per microgram of RNA injected. The other peak
of activity sedimented as 16S in size and contained about half the
activity of the slower sedimenting peak. Each of these activity
peaks appears to be due to IFN-.gamma., since no activity was
observed when the same fractions were assayed on a bovine cell line
(MDBK) which is not protected by human IFN-.gamma.. Both
IFN-.alpha. activity and IFN-.beta. activity would have been easily
detected with the MDBK assay (5).
Fractionation of mRNA (200 .mu.g) was also performed by
electrophoresis through acid urea agarose gels. The slab agarose
gel (37, 38) was composed of 1.75 percent agarose, 0.025M sodium
citrate, pH 3.8 and 6M urea. Electrophoresis was performed for 7
hours at 25 milliamp and 4.degree. C. The gel was then fractionated
with a razor blade. The individual slices were melted at 70.degree.
C. and extracted twice with phenol and once with chloroform.
Fractions were then ethanol precipitated and subsequently assayed
for IFN-.gamma. mRNA by injection into Xenopus laevis oocytes and
antiviral assay. Only one peak of activity was observed in gel
fractionated samples (FIG. 2). This peak comigrated with 18S RNA
and had an activity of 600 units/ml per microgram of injected RNA.
This activity also appeared to be IFN-.gamma. specific, since it
did not protect MDBK cells.
The size discrepancy between activity peaks observed on sucrose
gradients (12S and 16S) and acid urea gels (18S) may be explained
by the observation that these independent fractionation methods are
not performed under total denaturing conditions.
D. Preparation of a Colony Library Containing IFN-.gamma.
Sequences
3 .mu.g of gel-fractionated mRNA was used for the preparation of
double stranded cDNA by standard procedures (26, 39). The cDNA was
size fractionated on a 6 percent polyacrylamide gel. Two size
fractions were electroeluted, 800-1500 bp (138 ng) and 22 1500 bp
(204 ng). 35 ng portions of each size cDNA was extended with deoxyC
residues using terminal deoxynucleotidyl transferase (40) and
annealed with 300 ng of the plasmid pBR322 (41) which had been
similarly tailed with deoxyG residues at the PstI site (40). Each
annealed mixture was then transformed into E. coli K12 strain 294.
Approximately 8000 transformants were obtained with the 800-1500 bp
cDNA and 400 transformants were obtained with the >1500 bp
cDNA.
E. Screening of Colony Library for Induced cDNAs
The colonies were individually inoculated into wells of microtitre
plates containing LB (58)+5 .mu.g/ml tetracycline and stored at
-20.degree. C. after addition of DMSO to 7 percent. Two copies of
the colony library were grown up on nitrocellulose filters and the
DNA from each colony fixed to the filter by the Grunstein-Hogness
procedure (42).
.sup.32 P-labelled cDNA probes were prepared using 18S size gel
fractionated mRNA from induced and uninduced PBL cultures. Oligo
dT.sub.12-18 was the primer and reaction conditions have been
previously described (1). Filters containing 8000 transformants
from the 600-1500 bp cDNA size cut and 400 transformants from the
>1500 bp cDNA size cut were hybridized with 20.times.10.sup.6
cpm of induced .sup.32 P-cDNA. A duplicate set of filters was
hyrbidized with 20.times.10.sup.6 cpm of uninduced .sup.32 P-cDNA.
Hybridization was for 16 hours using conditions described by
Fritsch et al. (43). Filters were extensively washed (43) and then
exposed to Kodak XR-5 X-ray film with DuPont Lightning-Plus
intensifying screens for 16-48 hours. Each colony's hybridization
pattern with the two probes was compared. Approximately 40 percent
of the colonies clearly hybridized with both probes, while
approximately 50 percent of the colonies failed to hybridize with
either probe (presented in FIG. 3). 124 colonies hybridized
significantly with the induced probe but undetectably or more
weakly with the uninduced probe. These colonies were individually
inoculated into wells of microtitre plates, grown and transferred
to nitrocellulose filters, and hybridized with the same two probes,
as described above. Plasmid DNA isolated from each of these
colonies by a rapid method (44) was also bound to nitrocellulose
filters and hybridized (45) with the induced and uninduced probes.
DNA from 22 colonies hybridized with only the induced probe and
were termed "induced" colonies.
F. Characterization of Induced Colonies
Plasmid DNA was prepared from 5 of the induced colonies (46) and
used for characterization of the cDNA inserts. Restriction
endonuclease mapping of five induced plasmids (p67, p68, p69, p71
and p72) suggested that four had similar restriction nuclease maps.
These four (p67, p69, p71 and p72) each had four DdeI sites, 2
HinfI sites, and a single RsaI site in the cDNA insert. The fifth
plasmid (p68 ) contained a common DdeI fragment and appeared to be
a short cDNA clone related to the other four. The homology
suggested by restriction nuclease mapping was confirmed by
hybridization. A .sup.32 P-labelled DNA probe was prepared (47)
from a 600 bp DdeI fragment of the p67 plasmid and used for
hybridization (42) to the other induced colonies. All five of the
restriction nuclease mapped colonies cross-hybridized with this
probe, as did 17 other colonies of the 124 chosen in the
induced/uninduced screening. The length of cDNA insert in each of
these cross-hybridizing plasmids was determined by PstI digestion
and gel electrophoresis. The clone with the longest cDNA insert
appeared to be clone 69 with an insert length of 1200-1400 bp. This
DNA was used for all further experiments, and its restriction
endonuclease map is shown in FIG. 4.
The cDNA insert in p69 was demonstrated to be IFN-.gamma. cDNA by
its expression products, produced in three independent expression
systems, yielding antiviral activity, as described in more detail
infra.
G. Sequence Analysis of cDNA Insert of p69
The complete nucleotide sequence of the plasmid p69 cDNA insert was
determined by the dideoxynucleotide chain termination method (48)
after subcloning fragments into the M13 vector mp7 (49) and by the
Maxam-Gilbert chemical procedure (52). The longest open reading
frame encodes a protein of 166 amino acids, presented in FIG. 5.
The first residue encoded is the first met codon encountered in the
5' end of the cDNA. The first 20 residues at the amino terminus
probably serves as a signal sequence for the secretion of the
remaining 146 amino acids. This putative signal sequence has
features in common with other characterized signal sequences such
as size and hydrophobicity. Furthermore, the four amino acids found
at the putative cleavage sequence (ser-leu-gly-cys) are identical
with four residues found at the cleavage point of several leukocyte
interferons (LeIF B, C, D, F, and H, (2)). The encoded mature amino
acid sequence of 146 amino acids (hereinafter referred to as
"recombinant human immune interferon") has a molecular weight of
17,140.
There are two potential glycosylation positions (50) in the encoded
protein sequence, at amino acids 28 to 30 (asn-gly-thr) and amino
acids 100 to 102 (asn-tyr-ser). The existence of these positions is
consistent with the observed glucosylation of human IFN-.gamma. (6,
51). In addition, the only two cysteine residues (positions 1 and
3) are sterically too close to form a disulfide bridge, which is
consistent with the observed stability of IFN-.gamma. in the
presence of reducing agents such as .beta.-mercaptoethanol (51).
The deduced mature amino acid sequence is generally quite basic,
with 30 total lysine, arginine, and histidine residues and only 19
total aspartic acid and glutamic acid residues.
The mRNA structure of IFN-.gamma. as deduced from DNA sequence of
plasmid p69 is distinctively different from IFN-.alpha. (1, 2) or
IFN-.beta. (5) mRNA. As presented in FIG. 6, the coding region of
IFN-.gamma. is shorter while the 5' untranslated and 3'
untranslated regions are much longer than either IFN-.alpha. or
IFN-.beta..
H. Expression of Recombinant Human Immune Interferon in E. coli
With reference to FIG. 7, 50 .mu.g of plasmid p69 were digested
with PstI and the 1250 base pair insert isolated by gel
electrophoresis on a 6 percent polyacrylamide gel. Approximately 10
.mu.g of this insert was electroeluted from the gel. 5 .mu.g of
this PstI fragment was partially digested with 3 units of BstNI
(Bethesda Research Labs) for 15 minutes at 37.degree. C. and the
reaction mixture purified on a 6 percent polyacrylamide gel.
Approximately 0.5 .mu.g of the desired 1100 base pair BstNI-PstI
fragment was recovered. The two indicated deoxyoligonucleotides,
5'-dAATTCATGTGTTATTGTC and 5'-dTGACAATAACACATG (FIG. 7) were
synthesized by the phosphotriester method (53) and phosphorylated
as follows. 100 pmoles of each deoxyoligonucleotide were combined
in 30 .mu.l of 60 mM Tris-HCl (pH 8), 10 mM MgCl.sub.2, 15 mM
.beta.-mercaptoethanol and 240 .mu.Ci (.gamma.-.sup.32 P)ATP
(Amersham, 5000 Ci/mmole). 12 units of T4 polynucleotide kinase
were added and the reaction allowed to proceed at 37.degree. C. for
30 minutes. 1 .mu.l of 10 mM ATP wa added and the reaction allowed
to proceed an additional 20 minutes. After .phi.-OH/CHCl.sub.3
extraction the oligomers were combined with 0.25 .mu.g of the
BstNI-PstI 1100 base pair fragment and ethanol precipitated. These
fragments were ligated at 20.degree. C. for 2 hours in 30 .mu.l of
20 mM Tris-HCl (pH 7.5), 10 mM MgCl.sub.2, 10 mM dithiothreitol,
0.5 mM ATP and 10 units T4 DNA ligase. The mixture was digested for
1 hour with 30 units of PstI and 30 units of EcoRI (to eliminate
polymerization through ligation of cohesive termini) and
electrophoresed on a 6 percent polyacrylamide gel. The 1115 base
pair product (110,000 cpm) was recovered by electroelution.
The plasmid pLeIF A trp 103 (FIG. 7) is a derivative of the plasmid
pLeIF A 25 (1) in which the EcoRI site distal to the LeIF A gene
has been removed (27). 3 .mu.g of pLeIF A trp 103 was digested with
20 units of EcoRI and 20 units of PstI for 90 minutes at 37.degree.
C. and electrophoresed on a 6 percent polyacrylamide gel. The large
(.about.3900 base pair) vector fragment was recovered by
electroelution. The 1115 base pair EcoRI-PstI IFN-.gamma. DNA
fragment was ligated into 0.15 .mu.g of this prepared vector.
Transformation of E. coli K-12 strain 294 (ATCC No. 31446) gave 120
tetracycline resistant colonies. Plasmid DNA was prepared from 60
of these transformants and digested with EcORI and PstI. Three of
these plasmids contained the desired 1115 base pair EcoRI-PstI
fragment. DNA sequence analysis verified that these plasmids had
the desired nucleotide sequence at the junctions between the trp
promoter, synthetic DNA and cDNA. One of these plasmids
pIFN-.gamma. trp 48 was chosen for additional study. This plasmid
was used to transform the E. coli K-12 strain W3110 (ATCC No.
27325).
I. Gene Structure of the IFN-.gamma. Coding Sequence
The structure of the gene coding for IFN-.gamma. was analyzed by
Southern hybridization. In this procedure (54), 5 micrograms of
high molecular weight human lymphocyte DNA (prepared as in 55) is
digested to completion with various restriction endonucleases,
electrophoresed on 1.0 percent agarose gels (56), and blotted to a
nitrocellulose filter (54). A .sup.32 P-labelled DNA probe was
prepared (47) from a 600 bp DdeI fragment of the cDNA insert of p69
and hybridized (43) with the nitrocellulose-DNA blot. 10.sup.7
counts per minute of the probe were hybridized for 16 hours and
then washed as described (43). Eight genomic DNA samples from
different human donors were digested with the EcoRI restriction
endonuclease and hybridized with the p69 .sup.32 P-labelled probe.
As presented in FIG. 9, two clear hybridization signals are
observed with sizes of 8.8 kilobase pairs (kbp) and 2.0 kbp as
estimated by comparison of mobilities with HindIII digested
.lambda.DNA. This could be the result of two IFN-.gamma. genes or a
single gene split by an EcoRI site. Since the p69 cDNA contains no
EcoRI site, an intervening sequence (intron) with an internal EcoRI
site would be necessary to explain a single gene. To distinguish
between these possibilities, another Southern hybridization was
performed with the same probe against five other endonuclease
digestions of a single human DNA (FIG. 10). Two hybridizing DNA
fragments were observed with two other endonuclease digests, PvuII
(6.7 kbp and 4.0 kbp) and HincII (2.5 kbp and 2.2 kbp). However,
three endonuclease digestion patterns provide only a single
hybridizing DNA fragment: HindIII (9.0 kbp), BglII (11.5 kbp) and
BamHI (9.5 kbp). Two IFN-.gamma. genes would have to be linked at
an unusually close distance (less than 9.0 kbp) to be contained
within the same HindIII hybridizing fragment. This result suggests
that only a single homologous IFN-.gamma. gene (unlike the many
related IFN-.alpha. genes) is present in human genomic DNA and that
this gene is split by one or more introns containing EcoRI, PvuII,
and HincII sites. This prediction was supported by hybridization of
a .sup.32 P-labelled (47) fragment prepared from just the 3'
untranslated region of the cDNA from p69 (130 bp DdeI fragment from
860 bp to 990 bp in FIG. 5) against an EcoRI digest of human
genomic DNA. Only the 2.0 kbp EcoRI fragment hybridized to this
probe, suggesting that this fragment contains the 3' untranslated
sequences, while the 8.8 kbp EcoRI fragment contains the 5'
sequences. The gene structure of IFN-.gamma. (one gene with at
least one intron) is distinctly different from IFN-.alpha.
(multiple genes (2) without introns (56)) or IFN-.beta. (one gene
with no introns (57)).
J. Preparation of Bacterial Extracts
An overnight culture of E. coli W3110/pIFN-.gamma. trp 48 in Luria
broth+5 micrograms per ml tetracycline was used to inoculate M9
(58) medium containing 0.2 percent glucose, 0.5 percent casamino
acids, and 5 micrograms per ml tetracycline at a 1:100 dilution.
Indole acrylic acid was added to a final concentration of 20
micrograms per ml when A.sub.550 was between 0.1 and 0.2. Ten ml
samples were harvested by centrifugation at A.sub.550 =1.0 and
resuspended immediately in 1 ml phosphate buffered saline
containing 1 mg per ml bovine serum albumin (PBS-BSA). Cells were
opened by sonication and cleared of debris by centrifugation. The
supernatants were stored at 4.degree. C. until assay. Interferon
activity in the supernatants was determined to be 250 units/ml by
comparison with IFN-.alpha. standards by the cytopathic effect
(CPE) inhibition assay.
K. Transformation of Yeast/Strains and Media
Yeast strains were transformed as previously described (59). E.
coli strain JA300 (thr leuB6 thi thyA trpC1117 hsdm.sup.-
hsdR.sup.-0 str.sup.R) (20) was used to select for plasmids
containing functional TRPI gene. Yeast strain RH218 having the
genotype (a trp1 gal2 SUC2 mal CUPI) (18) was used as yeast
transformation host. RH218 has been deposited without restriction
in the American Type Culture Collection, ATCC No. 44076. M9
(minimal medium) with 0.25 percent casamino acids (CAA) and LB
(rich medium) were as described by Miller (58) with the addition of
20 .mu.g/ml ampicillin (Sigma) after media is autoclaved and
cooled. Yeast were grown on the following media: YEPD contained 1
percent yeast extract, 2 percent peptone and 2 percent glucose
.+-.3 percent Difco agar. YNB+CAA contained 6.7 grams of yeast
nitrogen base (without amino acids) (YNB) (Difco), 10 mg of
adenine, 10 mg of uracil, 5 grams CAA, 20 grams glucose and .+-.30
grams agar per liter.
L. Construction of Yeast Expression Vector
1. 10 .mu.g of YRp7 (14, 15, 16) was digested with EcoRI. Resulting
sticky DNA ends were made blunt using DNA Polymerase I (Klenow
fragment). Vector and insert were run on 1 percent agarose (SeaKem)
gel, cut from the gel, electroeluted and extracted 2.times. with
equal volumes of chloroform and phenol before precipitation with
ethanol. The resulting blunt end DNA molecules were then ligated
together in a final volume of 50 .mu.l for 12 hours at 12.degree.
C. This ligation mix was then used to transform E. coli strain
JA300 to ampicillin resistance and tryptophan prototrophy. Plasmids
containing the TRPI gene in both orientations were isolated. pFRW1
had the TRPI gene in the same orientation as YRp7 while pFRW2 had
the TRPI gene in the opposite orientation.
20 .mu.g of pFRW2 was linearized with HindIII and electrophoresed
on a 1 percent agarose gel. Linear molecules were eluted from the
gel and 200 ng were then ligated with 500 ng of the 3.1 kb HindIII
insert of plasmid pB1 (13) which is a restriction fragment
containing the yeast 3-phosphoglycerate kinase gene. The ligation
mix was used to transform E. coli strain 294 to ampicillin
resistance and tetracycline sensitivity. Plasmid prepared from one
such recombinant had an intact TRP1 gene with the 3.1 kbp HindIII
fragment from pB1 inert DNA in the HindIII site of the tetracycline
resistance gene. This plasmid is pFRM31. 5 .mu.g of pFRM31 was
completely digested with EcoRI, extracted twice with phenol and
chloroform then ethanol precipitated. The cohesive ends of the
molecule were filled in using DNA Polymerase I (Klenow fragment) in
a reaction which was made 250 .mu.M in each deoxynucleoside
triphosphate. The reaction was performed for 20 minutes at
14.degree. C. at which time the DNA was extracted two times with
phenol-chloroform, and then precipitated with ethanol. The
resuspended DNA was then completely digested with ClaI and
electrophoresed on a 6 percent acrylamide gel. The vector fragment
was eluted from the gel, phenol-chloroform extracted and ethanol
precipitated.
The six N-terminal amino acids of the 3-phosphoglycerate kinase
enzyme purified from humans are as follows: ##STR1##
One of the translational reading frames generated from the DNA
sequence of the 141 bp Sau3A-to-Sau3A restriction fragment
(containing the internal HincII site; see PGK restriction map FIG.
11) produces the following amino acid sequence. ##STR2##
After removal of initiator methionine, it is seen that PGK
N-terminal amino acid sequence has 5 of 6 amino acid homology with
N-terminal amino acid sequence of human PGK.
This sequencing result suggested that the start of the yeast PGK
structural gene is coded for by DNA in the 141 bp Sau3A restriction
fragment of pB1. Previous work (20) has suggested that the DNA
sequences specifying the PGK mRNA may reside in this area of the
HindIII fragment. Further sequencing of the 141 bp Sau3A fragment
gives more DNA sequence of the PGK promoter (FIG. 12).
A synthetic oligonucleotide with the sequence 5'ATTTGTTGTAAA3' was
synthesized by standard methods (Crea et al., Nucleic Acids Res. 8,
2331 (1980)). 100 ng of this primer was labeled at the 5' end using
10 units of T4 polynucleotide kinase in a 20 .mu.l reaction also
containing 200 .mu.Ci of [.gamma..sup.32 -P] ATP. This labeled
primer solution was used in a primer-repair reaction designed to be
the first step in a multi-step process to put an EcoRI restriction
site in the PGK 5'-flanking DNA just preceding PGK structure gene
sequence.
100 .mu.g of pB1 (20) was completely digested with HaeIII then run
on a 6 percent polyacrylamide gel. The uppermost band on the
ethidum stained gel (containing PGK promoter region) was isolated
by electroelution as described above. This 1200 bp HaeIII piece of
DNA was restricted with HincII then run on a 6 percent acrylamide
gel. The 650 bp band was isolated by electroelution. 5 .mu.g of DNA
was isolated. This 650 bp HaeIII-to-HincII piece of DNA was
resuspended in 20 .mu.l H.sub.2 O, then mixed with the 20 .mu.l of
the phosphorylated primer solution described above. This mixture
was 1.times. phenol-chloroform extracted then ethanol precipitated.
Dried DNA was resuspended in 50 .mu.l of H.sub.2 O and then heated
in a boiling water bath for seven minutes. This solution was then
quickly chilled in a dry ice-ethanol bath (10-20 seconds) then
transferred to an ice-water bath. To this solution was added 50
.mu.l of a solution containing 10 .mu.l of 10.times. DNA polymerase
I buffer (Boehringer Mannheim), 10 .mu.l of a solution previously
made 2.5 mM in each deoxynucleoside triphosphate (dATP, dTTP, dGTP
and dCTP), 25 .mu.l of H.sub.2 O and 5 units of DNA Polymerase I,
Klenow fragment. This 100 .mu.l reaction was incubated at
37.degree. C. for 4 hours. The solution was then 1.times.
phenol-chloroform extracted, ethanol precipitated, dried by
lyophilization then exhaustively restricted with 10 units of Sau3A.
This solution was then run on a 6 percent acrylamide gel. The band
corresponding to 39 bp in size was cut from the gel then isolated
by electroelution described above. This 39 bp band has one blunt
end and one Sau3A sticky end. This fragment was cloned into a
modified pFIF trp 69 vector (5). 10 .mu.g of pFIF trp 69 was
linearized with XbaI, 1.times. phenol chloroform extracted, then
ethanol precipitated. The XbaI sticky end was filled in using DNA
Polymerase I Klenow fragment in a 50 .mu.l reaction containing 250
.mu.M in each nucleoside triphosphate. This DNA was cut with BamHI
then run on a 6 percent acrylamide gel. The vector fragment was
isolated from the gel by electroelution then resuspended in 20
.mu.l H.sub.2 O. 20 ng of this vector was ligated with 20 ng of the
39 bp fragment prepared above for 4 hours at room temperature.
One-fifth of the ligation mix was used to transform E. coli strain
294 to ampicillin resistance (on LB +20 .mu.g/ml amp plates.
Plasmids from the transformants were examined by a quick screen
procedure (44). One plasmid, pPGK-39 was selected for sequence
analysis. 20 .mu.g of this plasmid was digested with XbaI, ethanol
precipitated then treated with 1000 units of bacterial alkaline
phosphase at 68.degree. C. for 45 min. The DNA was 3.times.
phenol-chloroform extracted, then ethanol precipitated. The
dephosphorylated ends were then labeled in a 20 .mu.l reaction
containing 200 .mu.Ci of [.gamma..sup.32 -P] ATP and 10 units of
T.sub.4 polynucleotide kinase. The plasmid was cut with SalI and
run on a 6 percent acrylamide gel.
The labeled insert band was isolated from the gel and sequenced by
the chemical degradation method (52). The DNA sequence at the
3'-end of this promoter piece was as expected.
2. Construction of 312 bp PvuI-to-EcoRI PGK Promoter Fragment
25 .mu.g of pPGK-39 (FIG. 13) was simultaneously digested with SalI
and XbaI (5units each) then electrophoresed on a 6 percent gel. The
390 bp band countaining the 39 bp promoter piece was isolated by
electroelution. The resuspended DNA was restricted with Sau3A then
electrophoresed on an 8 percent acrylamide gel. The 39 bp PGK
promoter band was isolated by electroelution. This DNA contained 39
bp of the 5' end of the PGK promoter on a Sau3A-to-XbaI
fragment.
25 .mu.g of pB1 was restricted with PvuI and KpnI then
electrophoresed on a 6 percent acrylamide gel. The 0.8 kbp band of
DNA was isolated by electroelution, then restricted with Sau3A and
electrophoresed on a 6 percent acrylamide gel. The 265 bp band from
the PGK promoter (FIG. 11) was isolated by electroelution.
This DNA was then ligated with the 39 bp promoter fragment from
above for two hours at room temperature. The ligation mix was
restricted with XbaI and PvuI then electrophoresed on a 6 percent
acrylamide gel. The 312 bp Xba-to-PvuI restriction fragment was
isolated by electroelution, then added to a ligation mix containing
200 ng of pBR322 (41) (previously isolated missing the 162 bp
PvuI-to-PstI restriction fragment) and 200 ng of the XbaI-to-PstI
LeIF A cDNA gene previously isolated from 20 .mu.g of pLeIF trp A
25. This three-factor-ligation mix was used to transform E. coli
strain 294 to tetracycline resistance. Transformant clonies were
miniscreened (44) and one of the colonies, pPGK-300 was isolated as
having 304 bp of PGK 5'-flanking DNA fused to the LeIF A gene in a
pBR322 based vector. The 5' end of the LeIF A gene has the
following sequence: 5'-CTAGAATTC-3'. Thus fusion of the XbaI site
from the PGK promoter fragment into this sequence allows for the
addition to the XbaI site an EcoRI site. pPGK-300 thus contains
part of the PGK promoter isolated in a PvuI-to-EcoRI fragment.
3. Construction of a 1500 bp EcoRI-to-EcoRI PGK Promoter
Fragment
10 .mu.g of pB1 was digested with PvuI and EcoRI and run on a 6
percent acrylamide gel. The 1.3 kb PvuI-to-EcoRI DNA band from the
PGK 5'-flanking DNA was isolated by electroelution. 10 .mu.g of
pPGK-300 was digested with EcoRI and PvuI and the 312 bp promoter
fragment was isolated by electroelution after electrophoresing the
digestion mix on a 6 percent acrylamide gel. 5 .mu.g of pFRL4 was
cut with EcoRI, ethanol precipitated then treated with bacterial
alkaline phosphatase at 68.degree. C. for 45 minutes. After three
extractions of DNA with phenol/chloroform, ethanol precipitation,
and resuspension in 20 ml of H.sub.2 O; 200 ng of the vector was
ligated with 100 ng of 312 by EcoRI-to-PvuI DNA from pPGK-300 and
100 ng of EcoRI-to-PvuI DNA from pB1. The ligation mix was used to
transform E. coli strain 294 to ampicillin resistance. One of the
transformants obtained was pPGK- 1500. This plasmid contains the
1500 bp PGK promoter fragment as an EcoRI-to-EcoRI or
HindIII-to-EcoRI piece of DNA.
10 .mu.g of pPGK-1500 was completely digested with ClaI and EcoRI
then the digestion mix was electrophoresed on a 6 percent
acrylamide gel. The 900 bp fragment containing the PGK promoter was
isolated by electroelution. 10 .mu.g of pIFN-.gamma. trp 48 was
completely digested with EcoRI and HincII and electrophoresed on a
6 percent acrylamide gel. The 938 bp band containing the directly
expressable IFN-.gamma. cDNA was isolated from the gel by
electroelution.
The yeast expression vector was constructed in a three factor
reaction by ligating together the PGK promoter fragment (on a
ClaI-to-EcoRI piece), the deleted pFRM-31 and the above isolated
IFN-.gamma. cDNA. The ligation reaction was incubated at 14.degree.
C. for 12 hours. The ligation mix was then used to transform E.
coli strain 294 to ampicillin resistance. Transformants were
analyzed for the presence of the properly constructed expression
plasmid, pPGK-IFN-.gamma. (FIG. 16). Plasmids containing the
expression system were used to transform spheroplasts of yeast
strain RH218 to tryptophan prototropy in agar missing tryptophan.
These recombinant yeast were then assayed for the presence of
recombinant human immune interferon.
Yeast extracts were prepared as follows: Ten ml cultures were grown
in YNB+CAA until reaching A.sub.660 .perspectiveto.1-2, collected
by centrifugation then resuspended in 500 .mu.l PBS buffer (20 mM
NaH.sub.2 PO.sub.4, pH=7.4, 150 mM NaCl). An equal volume of glass
beads (0.45-0.5 mm) were added and the mixture was then vortexed
for 2'. The extracts were spun 30 seconds at 14,000 rpm and
supernatant removed: Interferon activity in the supernatant was
determined to be 16,000 units/ml by comparison with IFN-.alpha.
standard using the CPE inhibition assay.
M. Construction of Cell Culture Vector pSV.gamma.69
The 342 base pair HindIII-PvuII fragment encompassing the SV40
origin was converted to an EcoRI restriction site bound fragment.
The HindIII site was converted by the addition of a synthetic
oligomer (5'dAGCTGAATTC) and the PvuII site was converted by
blunt-end ligation into an EcoRI site filled in using Polymerase I
(Klenow fragment). The resulting EcoRI fragment was inserted into
the EcoRI site of pML-1 (28). A plasmid with the SV40 late promoter
oriented away from the amp.sup.R gene was further modified by
removing the EcoRI site nearest the amp.sup.R gene of pML-1
(27).
The 1023 base pair HpaI-BglII fragment of cloned HBV DNA (60) was
isolated and the HpaI site of hepatitis B virus (HBV) converted to
an EcoRI site with a synthetic oligomer (5'dGCGAATTCGC). This
EcoRI-BglII bounded fragment was directly cloned into the
EcoRI-BamHI sites of the plasmid described above carrying the
origin of SV40.
Into the remaining EcoRI site was inserted the IFN-.gamma. gene on
a 1250 base pair PstI fragment of p69 after conversion of the PstI
ends to EcoRI ends. Clones were isolated in which the SV40 late
promoter preceded the structural gene of IFN-.gamma.. The resulting
plasmids were then introduced into tissue culture cells (29) using
a DEAE-dextran technique (61) modified such that the transfection
in the presence of DEAE-dextran was carried out for 8 hours. Cell
media was changed every 2-3 days. 200 microliters was removed daily
for interferon bioassay. Typical yields were 50-100 units/ml on
samples assayed three or four days after transfection.
The product of expression lacks the CYS-TYR-CYS N-terminal portion
of recombinant human immune interferon (Compare FIG. 5), supporting
the occurrence of signal peptide cleavage at the CYS-GLN junction
(amino acids 3 and 4 in FIG. 5) such that the mature polypeptide
would in fact consist of 143 amino acids.
N. Partial Purification of des-CYS-TYR-CYS Recombinant Human
interferon
In order to produce greater quantities of the des-CYS-LYS-CYS
recombinant human immune interferon, fresh monolayers of COS-7
cells in ten 10 cm plates were transfected with a total of 30 .mu.g
pDLIF3 in 110 mls DEAE-Dextran (200 .mu.g/ml DEAE Dextran 500,000
MW, 0.05M Tris pH 7.5, in DMEM). After 16 hrs. at 37.degree., the
plates were washed twice with DMEM. 15 mls fresh DMEM supplemented
with 10 percent f.b.s., 2 mM glutamine, 50 .mu./ml penicillin G,
and 50 mg/ml streptomycin was then added to each plate. The media
was replaced the following day with serum-free DMEM. Fresh
serum-free media was then added every day. The media collected was
kept at 4.degree. until either assayed or bound to CPG. The pooled
fractions from 3 and 4 day post-transfection samples were found to
contain essentially all of the activity.
0.5 g of CPG (controlled pore glass, Electronucleonics, CPG 350,
mesh size 120/200) were added to 100 ml of cell supernatant and the
mixture stirred for 3 hrs at 4.degree. C. After a short
centrifugation in a bench top centrifuge the settled beads were
packed into a column and thoroughly washed with 20 mM NaPO.sub.4 1M
NaCL 0.1 percent .beta.-mercaptoethanol pH 7.2. The activity was
then eluted with the same buffer containing 30 percent
ethyleneglycol followed by further elution with the above buffer
containing 50 percent ethyleneglycol. Basically all the activity
bound to the CPG. 75 percent of the eluted activity was found in
the fractions eluted with 30 percent ethyleneglycol. These
fractions were pooled and diluted with 20 mM NaPO.sub.4 1M NaCl pH
7.2 to a final concentration of 10 percent ethyleneglycol and
directly applied to a 10 ml Con A Sepharose (Pharmacia) column.
After a thorough wash with 20 mM NaPO.sub.4 1M NaCl pH 7.2 the
activity was eluted with 20 mM NaPO.sub.4 1M NaCl 0.2M
.alpha.-methyl-D-mannoside. A substantial amount of the activity
(55 percent) did not bind to this lectin. 45 percent of the
activity eluted with .alpha.-methyl-D-mannoside.
PHARMACEUTICAL COMPOSITIONS
The compounds of the present invention can be formulated according
to known methods to prepare pharmaceutically useful compositions,
whereby the human immune interferon product hereof is combined in
admixture with a pharmaceutically acceptable carrier vehicle.
Suitable vehicles and their formulation are described in
Remington's Pharmaceutical Sciences by E. W. Martin, which is
hereby incorporated by reference. Such compositions will contain an
effective amount of the interferon protein hereof together with a
suitable amount of vehicle in order to prepare pharmaceutically
acceptable compositions suitable for effective administration to
the host.
A. Parenteral Administration
The human immune interferon hereof may be parenterally administered
to subjects requiring antitumor, or antiviral treatment, and to
those exhibiting immunosuppressive conditions. Dosage and dose rate
may parallel that currently in use in clinical investigations of
other human interferons, e.g., about (1-10).times.10.sup.6 units
daily, and in the case of materials of purity greater than 1
percent, likely up to, e.g., 50.times.10.sup.6 units daily. Dosages
of IFN-.gamma. could be significantly elevated for greater effect
owing to the essential absence of human proteins other than
IIN-.gamma., which proteins in human derived materials may induce
certain untoward effects.
As one example of an appropriate dosage form for essentially
homogeneous IFN-.gamma. in parenteral form applicable herein, 3 mg.
IFN-.gamma. of specific activity of, say, 2.times.10.sup.8 U/mg may
be dissolved in 25 ml. 5N albumin (human)--USP, the solution passed
through a bacteriological filter and the filtered solution
aseptically subdivided into 100 vials, each containing
6.times.10.sup.6 units pure interferon suitable for parenteral
administration. The vials are preferably stored in the cold
(-20.degree. C.) prior to use.
BIOASSAY DATA
A. Characterization of Antiviral Activity
For antibody neutralizations, samples were diluted, if necessary,
to a concentration of 500-1000 units/ml with PBS-BSA. Equal volumes
of sample were incubated for 2-12 hrs at 4 degrees with serial
dilutions of rabbit antihuman leukocyte, fibroblast, or immune
interferon antisera. The anti-IFN-.alpha. and .beta. were obtained
from the National Institute of Allergy and Infectious Diseases. The
anti-IFN-.gamma. was prepared using authentic IFN-.gamma. (5-20
percent purity) purified from stimulated peripheral blood
lymphocytes. Samples were centrifuged 3 minutes at 12,000.times.g
for 3 min before assay. To test pH 2 stability, samples were
adjusted to pH 2 by addition of 1N HCl, incubated for 2-12 hrs at
4.degree., and neutralized by addition of 1N NaOH before assay. To
test sodium dodecyl sulfate (SDS) sensitivity, samples were
incubated with an equal volume of 0.2 percent SDS for 2-12 hrs at
4.degree. before assay.
B. Characterization of IFN-.gamma. Produced by E. coli and COS-7
cells
______________________________________ Antiviral Activity
(Units/ml) COS-7 E. coli cell/ W3110/ pSV.gamma.69 IFN- IFN- IFN-
pIFN-.gamma.trp48 Super- Treatment .alpha. .beta. .gamma. extract
natant ______________________________________ Untreated 375 125 250
250 62.5 pH 2 375 125 <6 <12 <4 0.1 percent SDS 375 --
<4 <8 -- Rabbit anti-IFN-.alpha. <8 125 250 250 187 Rabbit
anti-IFN-.beta. 375 <8 187 250 125 Rabbit anti-IFN-.gamma. 375
125 <4 <8 <4 ______________________________________
This table shows the characteristic behavior of IFN-.alpha., .beta.
and .gamma. standards after various treatments. The interferon
activity produced by E. coli W3110/pIFN-.gamma. trp 48 and by
COS-7/pSV.gamma.69 is acid-sensitive, SDS-sensitive, and
neutralized by immune interferon antiserum. It is not neutralized
by antibodies to IFN-.alpha. or .beta.. These data confirm that the
products produced in these systems are immune interferons and that
the cDNA insert of plasmid p69 codes for IFN-.gamma..
The immune interferon protein hereof has been defined by means of
determined DNA gene and deductive amino acid sequencing--cf. FIG.
5. It will be understood that for this particular interferon,
embraced herein, natural allelic variations exist and occur from
individual to individual. These variations may be demonstrated by
(an) amino acid difference(s) in the overall sequence or by
deletions, substitutions, insertions, inversions or additions of
(an) amino acid(s) in said sequence. All such allelic variations
are included within the scope of this invention.
Notwithstanding that reference has been made to particular
preferred embodiments, it will be further unerstood that the
present invention is not to be construed as limited to such, rather
to the lawful scope of the appended claims.
BIBLIOGRAPHY
1. Goeddel et al., Nature 287, 411 (1980).
2. Goeddel et al., Nature 290, 20 (1981).
3. Yelverton et al., Nucleic Acids Research 9, 731 (1981).
4. Gutterman et al., Annals of Int. Med. 93, 399 (180).
5. Goeddel et al., Nucleic Acids Research 8, 4057 (1980).
6. Yip et al., Process Natl. Acad. Sci. (USA) 78, 1601 (1981).
7. Taniguchi et al., Proc. Natl. Acad. Sci. (USA) 78, 3469
(1981).
8. Bloom, Nature 289, 593 (1980).
9. Sonnenfeld et al., Cellular Immunol. 40, 285 (1978).
10. Fleishmann et al., Infection and Immunity 26, 248 (1979).
11. Blalock et al., Cellular Immunology 49, 390 (1980).
12. Rudin et al., Proc. Natl. Acad. Sci. (USA) 77, 5928 (1980).
13. Crane et al., J. Natl. Cancer Inst. 61, 871 (1978).
14. Stinchcomb et al., Nature 282, 39 (1979).
15. Kingsman et al., Gene 7, 141 (1979).
16. Tschumper et al., Gene 10, 157 (1980).
17. Mortimer et al., Microbiological Reviews 44, 519 (198).
18. Miozzari et al., Journal of Bacteriology 134, 48 (1978).
19. Jones, Genetics 85, 23 (1977).
20. Hitzeman, et al., J. Biol. Chem. 255, 12073 (1980).
21. Hess et al., J. Adv. Enzyme Regul. 7, 149 (1968).
22. Holland et al., Biochemistry 17, 4900 (1978).
23. Bostian et al., Proc. Natl. Acad. Sci. (USA) 77, 4504
(1980).
24. The Molecular Biology of Yeast (Aug 11-18, 1981), Cold Spring
Harbor Laboratory, Cold Spring Harbor, N.Y.
25. Chambon, Ann. Rev. Biochemistry, 44, 613 (1975).
25a. Gluzman, Cell 23, 175 (1981).
26. Goeddel et al., Nature 281, 544 (1979).
27. Itakura et al., Science 198, 1056 (1977).
28. Lusky et al., Nature 293, 79 (1981).
29. Gluzman et al., Cold Spring Harbor Symp. Quant. Biol. 44, 293
(1980).
30. Fiers et al., Nature 273, 113 (1978).
31. Reddy et al., Science 200, 494 (1978).
32. Boedtker et al., Prog. in Nucleic Acids Res. Mol. Biol. 19, 253
(1976).
33. Berger et al., Biochemistry 18, 5143 (1979).
34. Aviv et al., Proc. Natl. Acad. Sci. USA 69, 1408 (1972).
35. Gurdon et al., J. Molec. Biol. 80, 539 (1975).
36. Stewart, The Interferon System. Springer, N.Y., p. 13-26
(1979).
37. Lehrach et al., Biochemistry 16, 4743 (1977).
38. Lynch et al., Virology 98, 251 (1979).
39. Wickens et al., J. Biol. Chem. 253, 2483 (1978).
40. Chang et al., Nature 275, 617 (1978).
41. Bolivar et al., Gene 2, 95 (1977).
42. Grunstein et al., Proc. Natl. Acad. Sci. U.S.A. 72, 3961
(1975).
43. Fritsch et al., Cell 19, 959 (1980).
44. Birnboim et al., Nucleic Acids Res. 7, 1513 (1979).
45. Kafatos et al., Nucleic Acids Res. 7, 1541 (1979).
46. Clewell et al., Biochemistry 9, 4428 (1970).
47. Taylor et al., Biochim. Biophys. Acta 442, 324 (1976).
48. Smith, Methods Enzymol. 65, 560 (1980).
49. Messing et al., Nucleic Acids Res. 9, 309 (1981).
50. Winzler, Hormonal Proteins and Peptides (ed. Li) Academic
Press, New York, p. 1 (1973).
51. Nathan et al., Nature 292, 842 (1981).
52. Maxam et al., Methods in Enzymol. 65, 490 (1980).
53. Crea et al., Proc. Natl. Acad. Sci. (USA) 75, 5765 (1978).
54. Southern, J. Molec. Biol. 98, 503 (1975).
55. Blin et al., Nucleic Acids Res. 3, 2303 (1976).
56. Lawn et al., Science 212, 1159 (1981).
57. Lawn et al., Nucleic Acids Res. 9, 1045 (1981).
58. Miller, Experiments in Molecular Genetics, p. 431-3, Cold
Spring Harbor Lab., Cold Spring Harbor, N.Y. (1972).
59. Beggs, Nature 275, 104 (1978).
60. Valenzuela et al., Animal Virus Genetics (ed. Fields, Jaenisch
and Fox) p. 57, Academic Press, New York (1980).
61. McCuthan et al., J. Natl. Cancer Inst. 41, 351 (1968).
* * * * *